Mederle A, Dumitrescu P, Borza C, Kundnani N
J Clin Med. 2025; 14(1.
PMID: 39797270
PMC: 11721703.
DOI: 10.3390/jcm14010188.
Yoshimitsu Y, Awaya T, Kawagoe N, Kunimasa T, Iijima R, Hara H
Diseases. 2024; 12(11).
PMID: 39589971
PMC: 11593014.
DOI: 10.3390/diseases12110297.
Wallbach M, Ajrab J, Bayram B, Pieper D, Schafer A, Luders S
Clin Kidney J. 2024; 17(9):sfae234.
PMID: 39258260
PMC: 11384228.
DOI: 10.1093/ckj/sfae234.
Ueno A, Onishi Y, Mise K, Yamaguchi S, Kanno A, Nojima I
BMJ Open Diabetes Res Care. 2024; 12(3).
PMID: 38816205
PMC: 11141182.
DOI: 10.1136/bmjdrc-2024-004237.
Cumhur Cure M, Cure E
Curr Pharm Des. 2024; 30(15):1149-1156.
PMID: 38566383
DOI: 10.2174/0113816128300162240322075423.
Do Sodium-Glucose Cotransporter 2 Inhibitors Decrease the Risk of Contrast-Associated Acute Kidney Injury in Patients with Type II Diabetes Mellitus?.
Cabuk G, Hazir K
Anatol J Cardiol. 2024; .
PMID: 38506315
PMC: 11059220.
DOI: 10.14744/AnatolJCardiol.2024.3980.
UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE.
Roddick A, Wonnacott A, Webb D, Watt A, Watson M, Staplin N
BMC Nephrol. 2023; 24(1):310.
PMID: 37880609
PMC: 10598949.
DOI: 10.1186/s12882-023-03339-3.
Empagliflozin and Renal Sodium-Hydrogen Exchange in Healthy Subjects.
Biancalana E, Rossi C, Raggi F, Distaso M, Trico D, Baldi S
J Clin Endocrinol Metab. 2023; 108(8):e567-e573.
PMID: 36794422
PMC: 10348461.
DOI: 10.1210/clinem/dgad088.
The Rationale and Evidence for SGLT2 Inhibitors as a Treatment for Nondiabetic Glomerular Disease.
Miyata K, Zhang S, Chan J
Glomerular Dis. 2023; 1(1):21-33.
PMID: 36751486
PMC: 9677741.
DOI: 10.1159/000513659.
Dapagliflozin reduces pulmonary vascular damage and susceptibility to atrial fibrillation in right heart disease.
Dai C, Kong B, Shuai W, Xiao Z, Qin T, Fang J
ESC Heart Fail. 2022; 10(1):578-593.
PMID: 36369767
PMC: 9871681.
DOI: 10.1002/ehf2.14169.
Does Dapagliflozin influence arterial stiffness and levels of circulating anti-aging hormone soluble Klotho in people with type 2 diabetes and kidney disease? Results of a randomized parallel group clinical trial.
Karalliedde J, Fountoulakis N, Stathi D, Corcillo A, Flaquer M, Panagiotou A
Front Cardiovasc Med. 2022; 9:992327.
PMID: 36247425
PMC: 9562264.
DOI: 10.3389/fcvm.2022.992327.
Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs.
Kim H, Kim S, Song S
Korean J Intern Med. 2022; 37(3):502-519.
PMID: 35368179
PMC: 9082447.
DOI: 10.3904/kjim.2021.515.
Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin-angiotensin-aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with....
Moustafa D, Imran Z, Ismail R, Rayan M, Gadeau A, Eldassouki H
Mol Biol Rep. 2022; 49(3):2321-2324.
PMID: 35102475
PMC: 8803405.
DOI: 10.1007/s11033-022-07183-w.
Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind, placebo-controlled....
Antlanger M, Domenig O, Kaltenecker C, Kovarik J, Rathkolb V, Muller M
Diabetes Obes Metab. 2022; 24(5):816-826.
PMID: 34984822
PMC: 9305250.
DOI: 10.1111/dom.14639.
Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System.
Puglisi S, Rossini A, Poli R, Dughera F, Pia A, Terzolo M
Front Endocrinol (Lausanne). 2021; 12:738848.
PMID: 34745006
PMC: 8567993.
DOI: 10.3389/fendo.2021.738848.
Sodium-Glucose Co-transporter-2 Inhibitor-Induced Pruritus: Itching for Answers.
Ali K, Mohammed S, Deonarine R, Teelucksingh S
Cureus. 2021; 13(8):e17573.
PMID: 34646628
PMC: 8480444.
DOI: 10.7759/cureus.17573.
Deletion of heterogeneous nuclear ribonucleoprotein F in renal tubules downregulates SGLT2 expression and attenuates hyperfiltration and kidney injury in a mouse model of diabetes.
Miyata K, Lo C, Zhao S, Zhao X, Chenier I, Yamashita M
Diabetologia. 2021; 64(11):2589-2601.
PMID: 34370045
PMC: 8992778.
DOI: 10.1007/s00125-021-05538-9.
Possible Preventative/Rehabilitative Role of Gliflozins in OSA and T2DM. A Systematic Literature Review-Based Hypothesis.
Monda V, Porcellati F, Strollo F, Fucili A, Monesi M, Satta E
Adv Ther. 2021; 38(8):4195-4214.
PMID: 34273093
PMC: 8342338.
DOI: 10.1007/s12325-021-01791-x.
Current Challenges and Future Perspectives of Renal Tubular Dysfunction in Diabetic Kidney Disease.
Duan S, Lu F, Song D, Zhang C, Zhang B, Xing C
Front Endocrinol (Lausanne). 2021; 12:661185.
PMID: 34177803
PMC: 8223745.
DOI: 10.3389/fendo.2021.661185.
Cardiorenal Protection in Diabetic Kidney Disease.
Lee J, Berzan E, Sridhar V, Odutayo A, Cherney D
Endocrinol Metab (Seoul). 2021; 36(2):256-269.
PMID: 33873265
PMC: 8090466.
DOI: 10.3803/EnM.2021.987.
